Prostate Cancer Active Surveillance Increasing in the US
From 2010 to 2015, active surveillance/watchful waiting increased from 14.5% to 42.1%, according to a new study.
Male Reproductive Cancers
Current Guidelines for Germline Genetic Testing in Prostate Cancer May Be Insufficient
A high percentage of men with prostate cancer have 1 or more potentially pathogenic germline variants, but would not be eligible for mutation testing under current NCCN guidelines.
Gene-Expression Assay for Metastatic Prostate Cancer Put to the Test
Almac Diagnostics has published analytical validation of a 70-gene assay designed for use with formalin-fixed paraffin-embedded samples.
MSI-H/dMMR Is Clinically Meaningful, Despite Being Uncommon in Prostate Cancer
Biomarkers of PD-1/PD-L1 checkpoint inhibitor response in prostate cancer could help stratify patients by response.
Overactive Bladder Linked to Prostate Cancer ADT
Compared with men receiving androgen deprivation therapy for prostate cancer, healthy men had a 98% decreased risk of overactive bladder, study finds.
Prostate Cancer Possibly Linked to Zinc Intake
In a Spanish study, the highest vs lowest tertile of dietary zinc intake was associated with a significant 66% increased relative risk of low-grade prostate cancer.
Statins Plus ADT May Up Survival in Advanced Prostate Cancer
Statin use by men receiving androgen deprivation therapy for advanced PCa was associated with decreased risk of overall and cancer-specific mortality.
Hypofractionated Radiotherapy May Benefit Patients With Localized Prostate Cancer
A study suggests HIMRT may have some advantages over CIMRT for treating men with localized prostate cancer.
New Surrogate Marker for ADT Evaluation Proposed
Time interval free of biochemical failure may be a potential surrogate end point in the setting of androgen-deprivation therapy evaluation in men with prostate cancer.
Does Epigenetic Therapy With Panobinostat Reduce CRPC Bicalutamide Resistance?
Panobinostat plus bicalutamide increased radiographic progression-free survival in patients with CRPC resistant to second-line antiandrogen therapy.
Next post in Prostate Cancer
